vigabatrin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gabamimetic agents	2819	68506-86-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vigabatrin (+/-)-4-Amino-5-hexenoic acid sabril vigabatrin hydrochloride vigabatrin HCl	The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. Molecular weight: 129.16 Formula: C6H11NO2 CLOGP: -2.22 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.13 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vigabatrin
(+/-)-4-Amino-5-hexenoic acid
sabril
vigabatrin hydrochloride
vigabatrin HCl

The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system.

Molecular weight: 129.16
Formula: C6H11NO2
CLOGP: -2.22
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -0.13
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	442.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Aug. 21, 2009	FDA	LUNDBECK LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1813.31	32.96	635	5856	124484	56161092
Drug withdrawal convulsions	651.35	32.96	116	6375	1246	56284330
Infantile spasms	423.16	32.96	64	6427	212	56285364
Product dose omission issue	281.93	32.96	213	6278	204540	56081036
Magnetic resonance imaging head abnormal	268.34	32.96	58	6433	1768	56283808
Retinogram abnormal	252.32	32.96	38	6453	121	56285455
Status epilepticus	247.54	32.96	85	6406	15056	56270520
Epilepsy	236.24	32.96	94	6397	25137	56260439
Death	227.22	32.96	235	6256	341191	55944385
Drug ineffective	204.14	32.96	370	6121	918619	55366957
Drug resistance	159.63	32.96	67	6424	20475	56265101
Irritability	154.40	32.96	73	6418	29515	56256061
Visual field defect	130.67	32.96	42	6449	6047	56279529
Somnolence	123.67	32.96	121	6370	163292	56122284
Multiple-drug resistance	108.68	32.96	33	6458	3941	56281635
Brain operation	101.30	32.96	21	6470	520	56285056
Aggression	87.07	32.96	45	6446	21961	56263615
Focal dyscognitive seizures	75.28	32.96	23	6468	2802	56282774
Tonic convulsion	74.45	32.96	19	6472	1196	56284380
Generalised tonic-clonic seizure	72.31	32.96	43	6448	27523	56258053
Change in seizure presentation	71.26	32.96	14	6477	262	56285314
Optic atrophy	64.72	32.96	17	6474	1199	56284377
Partial seizures	64.35	32.96	24	6467	5366	56280210
Respiratory distress	61.92	32.96	41	6450	31626	56253950
Abnormal behaviour	56.77	32.96	33	6458	20239	56265337
Intellectual disability	55.68	32.96	14	6477	830	56284746
Seizure cluster	49.19	32.96	10	6481	224	56285352
Retinal injury	48.98	32.96	10	6481	229	56285347
Bronchiolitis	48.68	32.96	16	6475	2466	56283110
Pneumonia	47.85	32.96	128	6363	406970	55878606
Hypotonia	47.03	32.96	22	6469	8655	56276921
Pain	46.47	32.96	10	6481	663174	55622402
Infantile spitting up	45.75	32.96	8	6483	76	56285500
Pneumonia aspiration	44.88	32.96	34	6457	32377	56253199
Temporal lobe epilepsy	44.20	32.96	10	6481	376	56285200
Respiratory failure	43.21	32.96	54	6437	95008	56190568
Epidural lipomatosis	43.03	32.96	8	6483	110	56285466
Retinal disorder	42.63	32.96	13	6478	1573	56284003
Coma blister	40.85	32.96	8	6483	147	56285429
Ophthalmological examination abnormal	39.61	32.96	7	6484	71	56285505
Nausea	38.82	32.96	20	6471	764158	55521418
Rhinovirus infection	37.99	32.96	15	6476	3907	56281669
Anticonvulsant drug level decreased	37.45	32.96	11	6480	1170	56284406
Neurotoxicity	37.18	32.96	23	6468	15772	56269804
Visual impairment	36.71	32.96	44	6447	74158	56211418
Blindness	36.35	32.96	24	6467	18397	56267179
Crying	35.36	32.96	25	6466	21415	56264161
Respiratory syncytial virus bronchiolitis	34.95	32.96	8	6483	317	56285259
Respiratory syncytial virus infection	33.20	32.96	15	6476	5446	56280130

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1733.25	37.12	672	5787	99096	31591789
Drug withdrawal convulsions	572.29	37.12	111	6348	1057	31689828
Infantile spasms	525.05	37.12	85	6374	236	31690649
Product dose omission issue	335.08	37.12	228	6231	105358	31585527
Drug ineffective	241.29	37.12	344	6115	395229	31295656
Magnetic resonance imaging head abnormal	239.26	37.12	55	6404	1238	31689647
Status epilepticus	218.87	37.12	85	6374	12021	31678864
Visual field defect	200.00	37.12	61	6398	4167	31686718
Retinogram abnormal	197.76	37.12	32	6427	88	31690797
Epilepsy	135.75	37.12	72	6387	20969	31669916
Death	116.15	37.12	237	6222	360332	31330553
Brain operation	106.52	37.12	22	6437	293	31690592
Infantile spitting up	100.25	37.12	16	6443	39	31690846
Somnolence	93.58	37.12	108	6351	99337	31591548
Visual impairment	83.39	37.12	61	6398	31218	31659667
Anticonvulsant drug level above therapeutic	80.48	37.12	20	6439	631	31690254
Partial seizures	80.04	37.12	31	6428	4335	31686550
Sudden unexplained death in epilepsy	71.38	37.12	17	6442	447	31690438
Excessive eye blinking	69.62	37.12	17	6442	498	31690387
Gaze palsy	68.72	37.12	21	6438	1439	31689446
Irritability	68.71	37.12	48	6411	22841	31668044
Ophthalmological examination abnormal	68.03	37.12	11	6448	30	31690855
Adverse event	62.07	37.12	40	6419	16665	31674220
Multiple-drug resistance	62.04	37.12	26	6433	4454	31686431
Optic atrophy	57.21	37.12	16	6443	802	31690083
Aggression	55.76	37.12	52	6407	37239	31653646
Eye movement disorder	55.46	37.12	23	6436	3838	31687047
Respiratory distress	50.57	37.12	47	6412	33506	31657379
Crying	50.30	37.12	24	6435	5573	31685312
Tonic convulsion	48.36	37.12	15	6444	1080	31689805
Postictal paralysis	48.23	37.12	11	6448	238	31690647
Abnormal behaviour	47.20	37.12	39	6420	23789	31667096
Posture abnormal	46.33	37.12	17	6442	2047	31688838
Acute kidney injury	45.39	37.12	3	6456	279711	31411174
Myoclonic epilepsy	43.97	37.12	14	6445	1098	31689787
Seizure cluster	43.35	37.12	9	6450	123	31690762
Respiratory syncytial virus infection	42.46	37.12	19	6440	3812	31687073
Change in seizure presentation	39.57	37.12	8	6451	95	31690790
Hypotonia	39.26	37.12	22	6437	7111	31683774
Generalised tonic-clonic seizure	38.18	37.12	32	6427	19899	31670986
Retinal disorder	38.17	37.12	12	6447	903	31689982
Pneumonia aspiration	37.89	37.12	43	6416	38683	31652202
Drug resistance	37.56	37.12	34	6425	23419	31667466

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	2081.77	30.99	798	8451	177164	70742031
Drug withdrawal convulsions	743.81	30.99	142	9107	2006	70917189
Infantile spasms	607.54	30.99	94	9155	322	70918873
Product dose omission issue	454.46	30.99	306	8943	217162	70702033
Retinogram abnormal	425.16	30.99	67	9182	266	70918929
Status epilepticus	400.89	30.99	142	9107	24384	70894811
Death	336.55	30.99	370	8879	509691	70409504
Epilepsy	275.35	30.99	123	9126	38661	70880534
Magnetic resonance imaging head abnormal	253.62	30.99	60	9189	2432	70916763
Visual field defect	205.54	30.99	66	9183	8372	70910823
Drug ineffective	193.97	30.99	395	8854	939357	69979838
Drug resistance	190.52	30.99	95	9154	38095	70881100
Somnolence	156.13	30.99	165	9084	215441	70703754
Irritability	150.14	30.99	81	9168	38144	70881051
Brain operation	147.72	30.99	30	9219	588	70918607
Partial seizures	131.96	30.99	47	9202	8158	70911037
Multiple-drug resistance	129.24	30.99	45	9204	7310	70911885
Respiratory distress	99.57	30.99	71	9178	54579	70864616
Aggression	93.03	30.99	65	9184	48381	70870814
Sudden unexplained death in epilepsy	89.14	30.99	20	9229	638	70918557
Tonic convulsion	88.61	30.99	25	9224	2037	70917158
Optic atrophy	87.13	30.99	24	9225	1791	70917404
Generalised tonic-clonic seizure	84.93	30.99	58	9191	41603	70877592
Anticonvulsant drug level above therapeutic	83.30	30.99	21	9228	1110	70918085
Seizure cluster	76.25	30.99	16	9233	370	70918825
Focal dyscognitive seizures	76.16	30.99	25	9224	3392	70915803
Pneumonia aspiration	74.34	30.99	63	9186	62226	70856969
Excessive eye blinking	73.48	30.99	20	9229	1427	70917768
Pneumonia	72.39	30.99	205	9044	596027	70323168
Bronchiolitis	69.56	30.99	24	9225	3790	70915405
Change in seizure presentation	67.26	30.99	14	9235	311	70918884
Abnormal behaviour	65.28	30.99	46	9203	34663	70884532
Respiratory disorder	62.57	30.99	47	9202	39076	70880119
Gaze palsy	60.89	30.99	20	9229	2718	70916477
Retinal disorder	59.30	30.99	18	9231	1893	70917302
Myoclonic epilepsy	55.47	30.99	17	9232	1847	70917348
Rhinovirus infection	53.01	30.99	23	9226	6710	70912485
Respiratory failure	52.09	30.99	85	9164	168650	70750545
Hypotonia	51.79	30.99	27	9222	11838	70907357
Electroencephalogram abnormal	51.57	30.99	21	9228	5237	70913958
Petit mal epilepsy	50.86	30.99	21	9228	5423	70913772
Respiratory syncytial virus infection	50.18	30.99	23	9226	7632	70911563
Crying	49.18	30.99	32	9217	21167	70898028
Postictal paralysis	49.17	30.99	11	9238	346	70918849
Viral infection	48.20	30.99	40	9209	38351	70880844
Posture abnormal	48.14	30.99	18	9231	3578	70915617
Pain	47.20	30.99	12	9237	628804	70290391
Nausea	46.30	30.99	27	9222	852061	70067134
Ophthalmological examination abnormal	46.22	30.99	8	9241	62	70919133
Eye movement disorder	44.56	30.99	21	9228	7419	70911776
Febrile convulsion	43.48	30.99	12	9237	901	70918294
Anticonvulsant drug level decreased	42.98	30.99	14	9235	1853	70917342
Temporal lobe epilepsy	42.54	30.99	10	9239	393	70918802
Acute kidney injury	42.06	30.99	6	9243	474618	70444577
Infantile spitting up	39.88	30.99	6	9243	16	70919179
Strabismus	39.74	30.99	14	9235	2350	70916845
Visual impairment	38.75	30.99	50	9199	80200	70838995
Intramyelinic oedema	36.79	30.99	5	9244	4	70919191
Coma blister	36.52	30.99	8	9241	228	70918967
Enterovirus infection	36.33	30.99	12	9237	1659	70917536
Dysmetria	34.25	30.99	10	9239	920	70918275
Encephalopathy	33.89	30.99	41	9208	61620	70857575
Arthralgia	33.41	30.99	12	9237	503378	70415817
Cerebral disorder	32.70	30.99	15	9234	4984	70914211
Gingival atrophy	32.14	30.99	6	9243	74	70919121
Lissencephaly	31.78	30.99	4	9245	0	70919195
Respiratory syncytial virus bronchiolitis	31.02	30.99	8	9241	463	70918732

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AG04	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Fatty acid derivatives
FDA EPC	N0000175753	Anti-epileptic Agent
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:63674	4-aminobutyrate transaminase inhibitors
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018682	GABA Agents
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
West syndrome	indication	28055006
Epilepsy characterized by intractable complex partial seizures	indication	442481002
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002
Visual field defect	contraindication	12184005
Reduced visual acuity	contraindication	13164000
Mood swings	contraindication	18963009
Kidney disease	contraindication	90708001	DOID:557
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.94	acidic
pKa2	10.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
4-aminobutyrate aminotransferase, mitochondrial	Enzyme	P80404	GABT_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Gamma-amino-N-butyrate transaminase	Enzyme		GABT_RAT		IC50	4.38	CHEMBL
4-aminobutyrate aminotransferase, mitochondrial	Enzyme		GABT_MOUSE		IC50	4.40	CHEMBL

External reference:

ID	Source
4025280	VUID
N0000171807	NUI
D00535	KEGG_DRUG
4025280	VANDF
C0048044	UMLSCUI
CHEBI:63638	CHEBI
CHEMBL89598	ChEMBL_ID
5665	PUBCHEM_CID
DB01080	DRUGBANK_ID
D020888	MESH_DESCRIPTOR_UI
5581	INN_ID
4821	IUPHAR_LIGAND_ID
GR120KRT6K	UNII
14851	RXNORM
15507	MMSL
36115	MMSL
52922	MMSL
d04669	MMSL
003774	NDDF
310283001	SNOMEDCT_US
322976008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0652	TABLET	500 mg	ORAL	ANDA	33 sections
Vigabatrin for oral solution USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0702	FOR SOLUTION	50 mg	ORAL	ANDA	33 sections
VIGADRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0556	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	35 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0201	TABLET	500 mg	ORAL	ANDA	31 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0470	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-521	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	33 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-521	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	33 sections
vigabatrin for oral solution	HUMAN PRESCRIPTION DRUG LABEL	1	31722-009	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	36 sections
Vigabatrin	Human Prescription Drug Label	1	42799-950	TABLET	500 mg	ORAL	ANDA	30 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	43598-651	TABLET, FILM COATED	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	43598-697	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-358	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	32 sections
Vigabatrin	Human Prescription Drug Label	1	59651-366	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	Human Prescription Drug Label	1	59651-367	TABLET	500 mg	ORAL	ANDA	31 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	64850-940	FOR SOLUTION	50 mg	ORAL	ANDA	33 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
VIGABATRIN	Human Prescription Drug Label	1	67877-674	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	31 sections
VIGABATRIN	Human Prescription Drug Label	1	67877-674	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	31 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	68180-521	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	31 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	69097-964	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	69097-964	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1424	TABLET	500 mg	ORAL	ANDA	28 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1425	FOR SOLUTION	500 mg	ORAL	ANDA	30 sections